The NCI60 human tumour cell line anticancer drug screen |
| |
Authors: | Shoemaker Robert H |
| |
Institution: | Screening Technologies Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Frederick, Maryland 21702-1201, USA. shoemaker@dtpax2.ncifcrf.gov |
| |
Abstract: | The US National Cancer Institute (NCI) 60 human tumour cell line anticancer drug screen (NCI60) was developed in the late 1980s as an in vitro drug-discovery tool intended to supplant the use of transplantable animal tumours in anticancer drug screening. This screening model was rapidly recognized as a rich source of information about the mechanisms of growth inhibition and tumour-cell kill. Recently, its role has changed to that of a service screen supporting the cancer research community. Here I review the development, use and productivity of the screen, highlighting several outcomes that have contributed to advances in cancer chemotherapy. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|